ABRAMS'o
CLINICALoDRUGoTHERAPY:oRATIONALESoFORoNURSINGoPRACTICE
,ABRAMS'oCLINICALoDRUGoTHERAPY:oRATIONALESoFORoNURSINGoPRACTICE
,ABRAMS'oCLINICALoDRUGoTHERAPY:oRATIONALESoFORoNURSINGoPRACTICE
, ABRAMS'oCLINICALoDRUGoTHERAPY:oRATIONALESoFORoNURSINGoPRACTICE
Chaptero1,oTheoFoundationoofoPharmacology:oQualityoandoSafety
1. Aowomanodiagnosedowithoobsessive–
compulsiveodisorderohasobeenoprescribedooralo paroxetineohydrochloride.oWhato isoth
eoexpectedoeffecto forothisoprescription?
A. Curativeoeffectoonosymptoms
B. Systemicoeffectoonosymptoms
C. Localoeffectoonosymptoms
D. Parenteraloeffectoonosymptoms
ANS:ooB
Rationale:oDrugsothato produceosystemicoeffectsoareotakenointootheobody,ocirculatedothrougho th
eobloodstreamotootheirositesoofoactionoinovariousobodyotissues,oandoeventuallyoeliminatedo fromot
heobody.oCurativeoagentsoareogivenotoo cureoaodiseaseoprocess.oInothisocase,oparoxetineo hydroc
hlorideowillocontrolotheosymptomsobuto notocureotheodisorder.oDrugsowitholocaloeffects,o suchoasosu
nscreenoandolocaloanesthetics,oactomainlyoatotheositeoofoapplication.o Paroxetineo hydrochlorideoi
sonotoadministeredoparenterally.oParenteraloagentsoareoadministeredo subcutaneously,o intramus
cularly,oorointravenously.
PTS: 1 REF: p.o3,oIntroduction OBJ: 1
NAT:o ClientoNeeds:oPhysiologicaloIntegrity:oPharmacologicaloandoParenteraloTherapieso T
OP: Chapter:o1:oTheoFoundationoofoPharmacology:o QualityoandoSafety
KEY:o IntegratedoProcess:oNursingoProcess
BLM:oo CognitiveoLevel:oUnderstand NOT:o MultipleoChoice
2. Aocliento hasobeenoprescribedoanoantibiotic.oThisomedicationoisoaonaturallyooccurring
substanceothatohasobeenocheG mR
icA
alDlyEm
SoBdOifOieSd.TWhaOtoM
.C isoanotheronameoforothisotypeoofomedication
?
A. Syntheticodrug
B. Semisyntheticodrug
C. Biotechnologyodrug
D. Prototypeodrug
ANS:ooB
Rationale:oSemisyntheticodrugso(e.g.,omanyoantibiotics)oareo naturallyooccurringosubstanceso thato
haveobeenochemicallyomodified.oSyntheticodrugsoareomoreostandardizedo inotheirochemicalo char
acteristics,o moreoconsistento inotheiroeffects,oandolessolikelyotoo produceoallergicoreactions.o Biotech
nologyodrugsoinvolveomanipulatingoDNAoandoRNAoandorecombiningogenesointoo hybridomolecul
esothato canobeo insertedointoolivingoorganisms.oPrototypeodrugsoareotheofirsto drugoofoaoparticula
rogroupotoo beodeveloped.
PTS: 1 REF: p.o3,oDrugoSources OBJ: 1
NAT:o ClientoNeeds:oPhysiologicaloIntegrity:oPharmacologicaloandoParenteraloTherapieso T
OP: Chapter:o1:oTheoFoundationoofoPharmacology:oQualityoandoSafety
KEY:o IntegratedoProcess:oNursingoProcess
BLM:oo CognitiveoLevel:oUnderstand NOT:o MultipleoChoice
3. Whichoclassificationoappliesotoomorphine?
A. Centralonervousosystemodepressant
B. Centralonervousosystemostimulant
ABRAMS'oCLINICALoDRUGoTHERAPY:oRATIONALESoFORoNURSINGoPRACTICE
CLINICALoDRUGoTHERAPY:oRATIONALESoFORoNURSINGoPRACTICE
,ABRAMS'oCLINICALoDRUGoTHERAPY:oRATIONALESoFORoNURSINGoPRACTICE
,ABRAMS'oCLINICALoDRUGoTHERAPY:oRATIONALESoFORoNURSINGoPRACTICE
, ABRAMS'oCLINICALoDRUGoTHERAPY:oRATIONALESoFORoNURSINGoPRACTICE
Chaptero1,oTheoFoundationoofoPharmacology:oQualityoandoSafety
1. Aowomanodiagnosedowithoobsessive–
compulsiveodisorderohasobeenoprescribedooralo paroxetineohydrochloride.oWhato isoth
eoexpectedoeffecto forothisoprescription?
A. Curativeoeffectoonosymptoms
B. Systemicoeffectoonosymptoms
C. Localoeffectoonosymptoms
D. Parenteraloeffectoonosymptoms
ANS:ooB
Rationale:oDrugsothato produceosystemicoeffectsoareotakenointootheobody,ocirculatedothrougho th
eobloodstreamotootheirositesoofoactionoinovariousobodyotissues,oandoeventuallyoeliminatedo fromot
heobody.oCurativeoagentsoareogivenotoo cureoaodiseaseoprocess.oInothisocase,oparoxetineo hydroc
hlorideowillocontrolotheosymptomsobuto notocureotheodisorder.oDrugsowitholocaloeffects,o suchoasosu
nscreenoandolocaloanesthetics,oactomainlyoatotheositeoofoapplication.o Paroxetineo hydrochlorideoi
sonotoadministeredoparenterally.oParenteraloagentsoareoadministeredo subcutaneously,o intramus
cularly,oorointravenously.
PTS: 1 REF: p.o3,oIntroduction OBJ: 1
NAT:o ClientoNeeds:oPhysiologicaloIntegrity:oPharmacologicaloandoParenteraloTherapieso T
OP: Chapter:o1:oTheoFoundationoofoPharmacology:o QualityoandoSafety
KEY:o IntegratedoProcess:oNursingoProcess
BLM:oo CognitiveoLevel:oUnderstand NOT:o MultipleoChoice
2. Aocliento hasobeenoprescribedoanoantibiotic.oThisomedicationoisoaonaturallyooccurring
substanceothatohasobeenocheG mR
icA
alDlyEm
SoBdOifOieSd.TWhaOtoM
.C isoanotheronameoforothisotypeoofomedication
?
A. Syntheticodrug
B. Semisyntheticodrug
C. Biotechnologyodrug
D. Prototypeodrug
ANS:ooB
Rationale:oSemisyntheticodrugso(e.g.,omanyoantibiotics)oareo naturallyooccurringosubstanceso thato
haveobeenochemicallyomodified.oSyntheticodrugsoareomoreostandardizedo inotheirochemicalo char
acteristics,o moreoconsistento inotheiroeffects,oandolessolikelyotoo produceoallergicoreactions.o Biotech
nologyodrugsoinvolveomanipulatingoDNAoandoRNAoandorecombiningogenesointoo hybridomolecul
esothato canobeo insertedointoolivingoorganisms.oPrototypeodrugsoareotheofirsto drugoofoaoparticula
rogroupotoo beodeveloped.
PTS: 1 REF: p.o3,oDrugoSources OBJ: 1
NAT:o ClientoNeeds:oPhysiologicaloIntegrity:oPharmacologicaloandoParenteraloTherapieso T
OP: Chapter:o1:oTheoFoundationoofoPharmacology:oQualityoandoSafety
KEY:o IntegratedoProcess:oNursingoProcess
BLM:oo CognitiveoLevel:oUnderstand NOT:o MultipleoChoice
3. Whichoclassificationoappliesotoomorphine?
A. Centralonervousosystemodepressant
B. Centralonervousosystemostimulant
ABRAMS'oCLINICALoDRUGoTHERAPY:oRATIONALESoFORoNURSINGoPRACTICE